ReviewInfection and drug resistance2026
Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance.
Review in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Tuberculosis (TB) is a leading cause of maternal mortality globally, especially for women living with HIV. TB preventive therapy (TPT) regimens treat TB infection and prevent progression to TB disease, but the components of these regimens, including isoniazid and rifamycins, often interact with HIV antiretroviral therapy (ART). There are limited data on drug-drug interactions, adverse pregnancy outcomes, and treatment success specifically in pregnant women living with HIV on ART but several new trials in pregnancy have recently been conducted. Objective: To perform a comprehensive narrative review of the literature outlining the available updated guidance and pregnancy considerations for implementing TPT in pregnant women living with HIV. Methods: We performed a narrative review to explore an in-depth yet flexible overview of TPT in pregnancy. Keywords related to pregnant women living with HIV on ART and TPT were used to identify manuscripts in PubMed from 1980 to 2026. All primary literature including various study designs was included; review manuscripts were excluded. Results: Three hundred and sixty-nine initial results were screened for relevance. Two hundred and seventy-seven abstracts were then chosen, and ultimately 111 manuscripts were extracted. These manuscripts and their reference lists were reviewed, and ultimately 78 references published from 1980 to 2026 were included for our review. We included six randomized controlled trials, 17 references related to clinical guidance, and 54 studies of various designs. Conclusion: Isoniazid and rifamycin-based TPT regimens appear safe and effective in pregnancy, but each with limitations. Newer short course combinations of these medications for TPT appear safe in pregnancy, although no clear guidelines exist. Lack of definitive trial data for pregnant women living with HIV results in conflicting national and international guidelines. Inclusion of this population in TPT trials is critical, especially countries with a high burden of HIV and TB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.